COLLPLANT HOLDI/S (NASDAQ:CLGN) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of COLLPLANT HOLDI/S (NASDAQ:CLGN) from a hold rating to a buy rating in a research note published on Tuesday morning, ValuEngine reports.

Separately, Zacks Investment Research raised shares of COLLPLANT HOLDI/S from a hold rating to a buy rating and set a $5.25 price target for the company in a research report on Tuesday, July 2nd.

NASDAQ CLGN opened at $3.35 on Tuesday. The company has a fifty day simple moving average of $4.21. COLLPLANT HOLDI/S has a 12-month low of $3.13 and a 12-month high of $8.73. The company has a current ratio of 1.66, a quick ratio of 1.41 and a debt-to-equity ratio of 0.95. The firm has a market cap of $13.30 million, a P/E ratio of -6.09 and a beta of 1.34.

COLLPLANT HOLDI/S (NASDAQ:CLGN) last posted its quarterly earnings results on Thursday, May 30th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.14. COLLPLANT HOLDI/S had a negative net margin of 22.03% and a negative return on equity of 4.79%. The business had revenue of $0.59 million during the quarter. As a group, sell-side analysts anticipate that COLLPLANT HOLDI/S will post -1.62 EPS for the current fiscal year.

About COLLPLANT HOLDI/S

CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe.

Read More: Blue-Chip Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for COLLPLANT HOLDI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COLLPLANT HOLDI/S and related companies with MarketBeat.com's FREE daily email newsletter.